Cholinergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cholinergic neurons are neurons that synthesize and release the neurotransmitter acetylcholine (ACh)[1]. In the central nervous system, these neurons play critical roles in cognitive function, attention, memory, and motor control[2]. Cholinergic neurons are particularly concentrated in specific brain regions including the basal forebrain[3], mesopontine tegmentum, and brainstem[4].
Cholinergic neurons possess distinct morphological and molecular characteristics that distinguish them from other neuronal populations[5]:
The basal forebrain contains the largest population of cortically projecting cholinergic neurons, comprising approximately 500,000-700,000 neurons in the human brain[15]:
The basal forebrain cholinergic system modulates cognitive processes through several mechanisms[19][20]:
Located in the pedunculopontine nucleus (PPN) and laterodorsal tegmental nucleus (LDT), these cholinergic populations regulate distinct functions[26]:
The brainstem contains several distinct cholinergic neuron populations[34]:
Cholinergic neurons demonstrate selective vulnerability in several neurodegenerative disorders, with patterns of loss that correlate with specific clinical phenotypes[38]:
The cholinergic system is profoundly affected in Alzheimer's Disease[39]:
Cholinergic dysfunction contributes to multiple motor and non-motor symptoms[45]:
Cholinergic deficits are often more severe than in AD[50]:
Single-cell transcriptomic analysis has revealed distinct cholinergic neuron populations with unique molecular signatures[64]:
Understanding cholinergic neuron dysfunction has led to several therapeutic approaches used in clinical practice[75]:
Acetylcholinesterase Inhibitors remain the mainstay of symptomatic treatment[76]:
These medications provide symptomatic benefit by increasing synaptic ACh availability[80], with greatest efficacy in early to moderate disease stages[81].
Research continues on disease-modifying approaches[82]:
Emerging strategies focus on preserving cholinergic neurons[88]:
The study of Cholinergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kuhl, D. E., et al. (1996). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 47(2), 463-471. https://doi.org/10.1212/WNL.47.2.463 ↩︎
Bartus, R. T., et al. (1982). The cholinergic hypothesis: historical perspective, rationale, and relevance to human therapeutics. Psychopharmacology, 78(2), 123-133. https://doi.org/10.1007/BF00422187 ↩︎
Mesulam, M. M., et al. (1992). Cholinergic neurons in the basal forebrain of the rat: distribution, cytoarchitecture, and connections. Journal of Comparative Neurology, 323(2), 209-229. https://doi.org/10.1002/cne.903230204 ↩︎
Heckers, S., et al. (1992). Cholinergic innervation of the thalamus in primates. Journal of Comparative Neurology, 320(1), 1-17. https://doi.org/10.1002/cne.903200102 ↩︎
Wu, H., et al. (2020). Molecular characterization of cholinergic neurons from the basal forebrain to the cerebral cortex. Neuroscience Bulletin, 36(10), 1145-1160. https://doi.org/10.1007/s12264-020-00548-w ↩︎
Oda, Y. (1999). Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathology International, 49(11), 921-937. https://doi.org/10.1046/j.1440-1827.1999.00993.x ↩︎
Weihe, E., et al. (1996). Expression of vesicular acetylcholine transporter in the human brain: identification of a novel cholinergic neuronal phenotype. Brain Research, 738(1), 1-12. https://doi.org/10.1016/S0006-8993(96)00767-4 ↩︎
Mesulam, M. M. (2013). Cholinergic neurons of the basal forebrain: historical development and overview. Journal of Neural Transmission, 120(1), 1-11. https://doi.org/10.1007/s00702-013-1070-5 ↩︎
Counts, S. E., et al. (2017). p75^NTR: A novel therapeutic target in Alzheimer's disease. Journal of Alzheimer's Disease, 56(2), 677-686. https://doi.org/10.3233/JAD-160722 ↩︎
Apparsundaram, S., et al. (2000). Molecular cloning and functional expression of the human brain choline transporter. Brain Research, 866(1-2), 238-243. https://doi.org/10.1016/S0006-8993(00)02237-9 ↩︎
Sims, N. R., et al. (1989). Morphological and biochemical changes in the cerebral cortex of the rat with age. Neurobiology of Aging, 10(5), 549-557. https://doi.org/10.1016/0197-4580(89)90073-6 ↩︎
Gulledge, A. T., et al. (2007). GABAergic circuits and the critical period for visual cortex plasticity. Developmental Neurobiology, 67(6), 757-775. https://doi.org/10.1002/dneu.20352 ↩︎
Zaborszky, L., et al. (2012). The modular organization of the basal forebrain corticopetal system. Journal of Neural Transmission, 119(1), 25-34. https://doi.org/10.1007/s00702-011-0770-y ↩︎
Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239-259. https://doi.org/10.1007/BF00308809 ↩︎
Arendt, T., et al. (2015). The cholinergic system in healthy aging and Alzheimer's disease. Current Alzheimer Research, 12(8), 743-756. https://doi.org/10.2174/1567205012666150713095509 ↩︎
Mesulam, M. M., et al. (1983). Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis in macaque. Journal of Comparative Neurology, 214(2), 170-197. https://doi.org/10.1002/cne.902140206 ↩︎
Frotscher, M., & Leranth, C. (1985). Cholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry: a combined light and electron microscopic study. Journal of Comparative Neurology, 239(2), 237-246. https://doi.org/10.1002/cne.902390210 ↩︎
Gaykema, R. P., et al. (1990). Pattern of direct projections from the diagonal band to hippocampus, olfactory bulb, and somatosensory cortex. Journal of Comparative Neurology, 297(1), 1-13. https://doi.org/10.1002/cne.902970102 ↩︎
Sarter, M., et al. (2005). Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Research Reviews, 48(1), 98-111. https://doi.org/10.1016/j.brainresrev.2004.08.006 ↩︎
Hasselmo, M. E. (2006). The role of acetylcholine in learning and memory. Current Opinion in Neurobiology, 16(6), 710-715. https://doi.org/10.1016/j.conb.2006.09.002 ↩︎
Pinto, J. G., et al. (2013). Acetylcholine modulates cortical visual processing through basal forebrain activation. Nature Neuroscience, 16(12), 1857-1863. https://doi.org/10.1038/nn.3553 ↩︎
Kilgard, M. P., et al. (2002). Cortical plasticity: beyond the critical period. Progress in Brain Research, 138, 29-41. https://doi.org/10.1016/S0079-6123(02)38064-9 ↩︎
Muir, J. L., et al. (1994). Role of cholinergic basal forebrain neurons in attention and working memory. Neuron, 12(3), 605-614. https://doi.org/10.1016/0896-6273(94)90215-4 ↩︎
Jones, B. E. (2005). Arousal systems of the brain. Sleep Medicine Reviews, 9(2), 153-167. https://doi.org/10.1016/j.smrv.2004.08.003 ↩︎
Sarter, M., & Bruno, J. P. (1997). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Research Reviews, 23(1-2), 28-46. https://doi.org/10.1016/S0165-0173(96)00015-4 ↩︎
Ryczko, D., & Dubuc, R. (2017). The pedunculopontine nucleus and reticulospinal system: towards a novel framework for understanding gait disorders. Journal of Neural Transmission, 124(5), 555-568. https://doi.org/10.1007/s00702-017-1707-x ↩︎
Pahapill, P. A., & Lozano, A. M. (2000). The pedunculopontine nucleus in Parkinson's disease: progressive supranuclear palsy and cortical dementia. Brain, 123(8), 1767-1783. https://doi.org/10.1093/brain/123.8.1767 ↩︎
Stewart, D. J., et al. (1985). The role of acetylcholine in the pedunculopontine-tegmental nucleus in the modulation of cortical arousal in the rat. Brain Research, 335(2), 285-293. https://doi.org/10.1016/0006-8993(85)90486-3 ↩︎
Kelley, B. J., et al. (2011). A role for the basal forebrain cholinergic system in sleep apnea. Sleep, 34(8), 1065-1072. https://doi.org/10.5665/SLEEP.1168 ↩︎
Jones, B. E. (2004). Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. Progress in Brain Research, 145, 157-169. https://doi.org/10.1016/S0079-6123(03)45011-5 ↩︎
Cai, Y. Q., et al. (2013). Role of M2, M3, and M4 muscarinic receptors in the nucleus accumbens in antinociception. Brain Research, 1499, 1-10. https://doi.org/10.1016/j.brainres.2012.12.038 ↩︎
Matsumura, M., et al. (1998). Pedunculopontine tegmental nucleus and gait control. Proceedings of the Japan Academy, Series B, 74(8), 149-161. https://doi.org/10.2183/pjab.74.149 ↩︎
Woolf, N. J., & Butcher, L. L. (1989). Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Research Bulletin, 23(6), 519-540. https://doi.org/10.1016/0361-9230(89)90158-2 ↩︎
Woolf, N. J. (1991). Cholinergic systems in mammalian brain and spinal cord. Progress in Neurobiology, 37(6), 475-524. https://doi.org/10.1016/0301-0082(91)90006-M ↩︎
Buttner-Ennever, J. A., & Buttner, U. (1992). The neuroanatomy of the oculomotor system. Reviews of Oculomotor Research, 5, 119-176. https://doi.org/10.1016/S0079-6123(08)60421-7 ↩︎
Travagli, R. A., et al. (2006). Brainstem circuits regulating gastric function. Annual Review of Physiology, 68, 279-305. https://doi.org/10.1146/annurev.physiol.68.040305.085297 ↩︎
Paxinos, G. (2013). The human nervous system. Academic Press. ↩︎
Shimohama, S., et al. (1998). Selective vulnerability of cholinergic neurons in the nucleus basalis to amyloid pathology. Neuroscience Letters, 251(3), 165-168. https://doi.org/10.1016/S0304-3940(98)00535-5 ↩︎
Coyle, J. T., et al. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 221(4614), 1182-1187. https://doi.org/10.1126/science.6314349 ↩︎
Arendt, T., et al. (1985). Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathologica, 61(2), 101-108. https://doi.org/10.1007/BF00697388 ↩︎
Baskerville, K. A., et al. (1997). Basal forebrain cholinergic system: a functional analysis and review. Neurochemistry International, 31(4), 509-530. https://doi.org/10.1016/S0197-0186(96)00151-7 ↩︎
Mufson, E. J., et al. (2008). Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Review of Neurotherapeutics, 8(11), 1703-1718. https://doi.org/10.1586/14737175.8.11.1703 ↩︎
Davies, P., & Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 308(8000), 1403. https://doi.org/10.1016/S0140-6736(76)91936-X ↩︎
Francis, P. T., et al. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 67(4), 558. https://doi.org/10.1136/jnnp.67.4.558 ↩︎
Bohnen, N. I., & Albin, R. L. (2011). The cholinergic system and Parkinson's disease. Behavioural Brain Research, 221(2), 564-573. https://doi.org/10.1016/j.bbr.2019.11.016 ↩︎
Jellinger, K. A. (1988). The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Huntington's disease. Journal of Neurology, 235(1), 1-9. https://doi.org/10.1007/BF00719409 ↩︎
Muller, M. L., & Bohnen, N. I. (2013). Cholinergic dysfunction in Parkinson's disease. Current Neurology and Neuroscience Reports, 13(9), 377. https://doi.org/10.1007/s11910-013-0377-7 ↩︎
Zhang, J., et al. (2018). Caveolin-1 and cholinergic dysfunction in the aging and Alzheimer's brain. Neurobiology of Aging, 64, 70-80. https://doi.org/10.1016/j.neurobiolaging.2017.12.014 ↩︎
Fothergill, T., et al. (2014). Freezing of gait in Parkinson's disease: the interplay between dopaminergic and cholinergic systems. Journal of Neural Transmission, 121(12), 1451-1460. https://doi.org/10.1007/s00702-014-1303-2 ↩︎
Tiraboschi, P., et al. (2002). Early neuropathology of cholinergic nuclei in Lewy body disease. Journal of Neural Transmission, 109(5), 689-702. https://doi.org/10.1007/s00702-002-0570-y ↩︎
Shiozaki, K., et al. (1999). Cholinergic activity and muscarinic receptor binding in the brains of patients with dementia with Lewy bodies. Psychogeriatrics, 1(1), 34-39. https://doi.org/10.1111/j.1479-8301.1999.tb00126.x ↩︎
Perry, E. K., et al. (1995). Visual hallucinations and the cholinergic system in dementia with Lewy bodies. Journal of Neurology, Neurosurgery & Psychiatry, 58(1), 96-100. https://doi.org/10.1136/jnnp.58.1.96 ↩︎
Ballard, C. G., et al. (2002). Visual hallucinations and cholinergic disease in Alzheimer's disease. Annals of Neurology, 52(4), 516-520. https://doi.org/10.1002/ana.10335 ↩︎
Mori, E., et al. (2012). Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Annals of Neurology, 71(6), 845-854. https://doi.org/10.1002/ana.22600 ↩︎
Jellinger, K. A. (2022). Neuropathology of progressive supranuclear palsy. Acta Neuropathologica, 143(3), 271-282. https://doi.org/10.1007/s00401-021-02374-6 ↩︎
Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. Lancet, 386(9996), 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3 ↩︎
Kuo, Y. M., et al. (2018). Cholinergic therapy for progressive supranuclear palsy: a systematic review and meta-analysis. Parkinsonism & Related Disorders, 54, 33-40. https://doi.org/10.1016/j.parkreldis.2018.04.020 ↩︎
Benarroch, E. E. (2013). Multiple system atrophy: autonomic pathophysiology. Clinical Autonomic Research, 23(2), 51-60. https://doi.org/10.1007/s10286-013-0186-z ↩︎
Gjerstad, M. D., et al. (2017). Cholinergic deficits in multiple system atrophy. Movement Disorders, 32(8), 1238-1245. https://doi.org/10.1002/mds.27048 ↩︎
Fanciulli, A., & Wenning, G. K. (2015). Multiple-system atrophy. New England Journal of Medicine, 372(3), 249-263. https://doi.org/10.1056/NEJMra1311488 ↩︎
Hedreen, J. C., et al. (1991). Selective loss of corticobasal cholinergic neurons in amyotrophic lateral sclerosis. Annals of Neurology, 30(5), 786. https://doi.org/10.1002/ana.410300516 ↩︎
Tyzio, R., et al. (2006). Cortical drive of cholinergic neurons in ALS. Brain Research, 1089(1), 138-146. https://doi.org/10.1016/j.brainres.2006.03.009 ↩︎
Morrison, K. E., et al. (2020). Cholinergic markers in ALS: relationship to cognitive and behavioral symptoms. Neurology, 94(15), e1589-e1598. https://doi.org/10.1212/WNL.0000000000009266 ↩︎
Zhong, S., et al. (2020). Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases. Nature Genetics, 52(11), 1158-1168. https://doi.org/10.1038/s41588-020-00721-x ↩︎
Cupp, C. J., & Uteshev, V. V. (2013). Alpha7 nicotinic acetylcholine receptors as therapeutic targets in Alzheimer's disease. Current Alzheimer Research, 10(3), 308-315. https://doi.org/10.2174/1567205011310030012 ↩︎
Bamber, N. I., et al. (2005). Neurotrophins and the cholinergic system in the CNS. Neurobiology of Aging, 26(6), 849-858. https://doi.org/10.1016/j.neurobiolaging.2004.10.006 ↩︎
Gielow, M. R., & Zaborszky, L. (2017). The basal forebrain cholinergic system: functional organization and alterations in aging. Neurobiology of Learning and Memory, 144, 108-118. https://doi.org/10.1016/j.nlm.2017.06.004 ↩︎
Simic, G., et al. (2021). Age-related changes of cholinergic neurons in the human basal forebrain. Neurobiology of Aging, 106, 48-65. https://doi.org/10.1016/j.neurobiolaging.2021.04.019 ↩︎
Alderson, H. L., et al. (2006). Pedunculopontine tegmental nucleus acetylcholine: in vivo release and control of REM sleep. Sleep, 29(10), 1321-1331. ↩︎
Zhang, L., et al. (2018). Glutamate cotransmission in cholinergic neurons. Brain Research Bulletin, 136, 12-17. https://doi.org/10.1016/j.brainresbull.2017.06.008 ↩︎
Van Dort, Z. E., et al. (2015). Pharmacological manipulation of the pedunculopontine nucleus in Parkinson's disease: a new therapeutic approach. Journal of Neural Transmission, 122(5), 661-668. https://doi.org/10.1007/s00702-014-1309-9 ↩︎
Sparks, D. L. (2002). The brainstem control of saccadic eye movements. Nature Reviews Neuroscience, 3(12), 952-964. https://doi.org/10.1038/nrn986 ↩︎
Kandel, E. R., et al. (2000). Principles of neural science. McGraw-Hill. ↩︎
Nieuwenhuys, R. (2013). The mesopontine rostral brain. Brain Structure and Function, 218(1), 1-28. https://doi.org/10.1007/s00429-012-0471-9 ↩︎
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, (1). https://doi.org/10.1002/14651858.CD005593 ↩︎
Raskind, M. A., et al. (2000). Tacrine and donepezil: therapeutic considerations. Journal of Clinical Psychiatry, 61(11), 858-864. ↩︎
Rogers, S. L., et al. (1998). Donepezil improves cognition and global function in Alzheimer disease. Clinical Therapeutics, 20(3), 439-451. https://doi.org/10.1016/S0149-2918(98)80120-6 ↩︎
Jann, M. W., et al. (2002). Rivastigmine: a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 22(7), 837-850. https://doi.org/10.1592/phco.22.11.837.33627 ↩︎
Maelicke, A., et al. (2001). Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dialogues in Clinical Neuroscience, 3(2), 75-85. https://doi.org/10.31887/DCNS.2001.3.2/aelicke ↩︎
Francis, P. T., & Perry, E. K. (2007). Cholinergic and dopaminergic biomarkers in Alzheimer's disease. Journal of Alzheimer's Disease, 12(2), 137-149. https://doi.org/10.3233/JAD-2007-12204 ↩︎
Raina, P., et al. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence panel for recommendations. Annals of Internal Medicine, 148(5), 379-397. https://doi.org/10.7326/0003-4819-148-5-200803040-00009 ↩︎
Schliebs, R., & Arendt, T. (2011). The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. Journal of Neural Transmission, 118(3), 339-353. https://doi.org/10.1007/s00702-010-0534-5 ↩︎
Medina, J. C., et al. (2020). Alpha-7 nicotinic receptor agonists for the treatment of Alzheimer's disease. Current Topics in Medicinal Chemistry, 20(22), 1935-1948. https://doi.org/10.2174/1568026620666200825124601 ↩︎
Fisher, A. (2008). M1 muscarinic agonists: major news in Alzheimer's disease therapy. Current Alzheimer Research, 5(1), 1-3. https://doi.org/10.2174/156720508783954740 ↩︎
Tuszynski, M. H., et al. (2005). A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine, 11(5), 551-555. https://doi.org/10.1038/nm1239 ↩︎
Tatard-Leonardi, V. M., et al. (2021). Stem cell therapy for cholinergic degeneration in Alzheimer's disease. Stem Cell Research & Therapy, 12(1), 1-15. https://doi.org/10.1186/s13287-021-02256-2 ↩︎
Fischer, D. L., et al. (2021). AAV2-mediated delivery of human NGF to the basal forebrain: a novel gene therapy approach for Alzheimer's disease. Molecular Therapy, 29, 1-15. https://doi.org/10.1016/j.ymthe.2021.06.015 ↩︎
Mufson, E. J., et al. (2003). Cholinergic plasticity in the forebrain of aged primates. Neurobiology of Aging, 24(6), 835-844. https://doi.org/10.1016/S0197-4580(02)00232-7 ↩︎
Poirier, J. (2005). Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiology of Aging, 26(3), 355-361. https://doi.org/10.1016/j.neurobiolaging.2004.10.003 ↩︎
van Praag, H., et al. (2005). Exercise enhances learning and hippocampal neurogenesis in aged mice. Journal of Neuroscience, 25(38), 8680-8685. https://doi.org/10.1523/JNEUROSCI.1731-05.2005 ↩︎
Sabbagh, M. N., et al. (2021). Can we prevent Alzheimer's disease? Expert consensus on primary prevention. Journal of Prevention of Alzheimer's Disease, 8(2), 228-234. https://doi.org/10.14283/jpad.2021.15 ↩︎